Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Panel Advises Expanding Use of Heart Implant

By Drug Discovery Trends Editor | March 19, 2010

COLLEGE PARK, Md. (AP) – Federal health advisers said an electronic heart implant should be approved for a large group of heart-disease patients who currently aren’t eligible for the device.

A Food and Drug Administration panel of cardiologists voted unanimously in favor of Boston Scientific’s heart-regulating device to treat mild heart failure, so long as the company tracks the long-term safety of patients.

The FDA is not required to follow the panel’s advice, though it often does. Currently the device is approved for moderate to severe heart failure.

A positive FDA decision would expand the market for the devices by tens of thousands of patients.

The device combines a defibrillator, which shocks the heart to correct irregular beats, with a resynchronization device to coordinate the pumping action of the heart. Currently most heart failure patients receive a defibrillator alone.

The two-in-one combination device is known as a cardiac resynchronization therapy defibrillator.

Boston Scientific Corp.’s presentation showed that patients implanted with a resynchronization defibrillator were 34 percent less likely to be hospitalized or experience other heart-related events when compared patients who only received a defibrillator. While there was no difference in death rate between the groups, panelists said the reduction in hospitalizations was enough to warrant approval.

“I think it’s a laudable and highly usable endpoint that alone justifies the approval,” said Dr. John Somberg of Rush University Medical Center.

Panelists discussed the fact that patients with a synchronization device experienced more adverse side effects than those with defibrillators. About 15 percent of patients with the combination device had complications, compared with 7.6 percent of defibrillator patients.

Considering those side effects and the lack of impact on lifespans, panelists unanimously said the company should be required to track patients long-term to confirm the device’s benefits.

“We need more evidence of whether it’s worth it to have some of these upfront complications in order to avoid more hospitalizations years down the road,” said panel member Dr. Michael Domanski, of the National Institutes of Health.

FDA is scheduled to make a final decision by mid-June.

Even with FDA approval, there could be stumbling blocks for widespread use of the device. Resynchronizers cost between $30,000 to $40,000, not including the cost of implantation. And patients with mild heart failure, who are not experiencing painful symptoms, might be reluctant to have surgery to get the device.

Sales growth of heart-pacing devices has been flat in recent years due to market saturation and safety concerns involving recalled devices. Boston Scientific Corp. and competitors Medtronic Inc. and St. Jude Medical Inc. are targeting patients with mild heart failure as the potential future market for their devices.

In the U.S., about 60,000 patients with severe heart disease get the devices every year, out of 5.5 million people who have heart failure. More than 3.8 million of those patients have mild to moderate heart failure.

Boston Scientific, which is based in Natick, Mass., does not separate sales of defibrillators and resynchronization implants, but the devices combined accounted for 15 percent of company revenue.

Date: March 18, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50